查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519529

2024-2032 年按治疗类型、疾病类型（肝炎、自体免疫疾病、非酒精性脂肪肝、癌症、遗传性疾病等）、最终用户和地区分類的肝病治疗市场报告

Liver Disease Treatment Market Report by Treatment Type, Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others), End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2023年全球肝病治疗市场规模达238亿IMARC Group。

肝臟是人体的重要器官，具有重要的功能，例如储存维生素和营养物质、清除血液中的有害物质以及维持体内化学物质的适当平衡。癌症、肝炎、自体免疫疾病和遗传性疾病是一些常见的肝臟疾病。这些疾病通常由感染、遗传、肥胖、糖尿病和免疫系统异常引起。一些广泛使用的肝病治疗技术包括疫苗、化疗、抗病毒药物、免疫球蛋白、皮质类固醇和免疫抑制剂。肝病治疗有助于胆固醇和荷尔蒙的排泄，增加胆汁的产生和酵素的活化。

肝病治疗市场趋势：

全球老年人口不断增加，容易患各种慢性疾病，包括肝病，这是推动市场成长的主要因素之一。饮食模式的变化和久坐的生活方式正在推动市场成长。此外，由于高胆固醇、肥胖、高血压和糖尿病导致的脂肪肝疾病的盛行率不断增加，有利于市场的成长。此外，各种技术进步，例如生物人工肝的发展，正在为市场成长提供动力。它利用再生肝细胞取代肝功能，广泛用于急性肝衰竭患者。与此一致的是，抗病毒药物的迅速采用，因为它们安全有效，有助于抑制乙型肝炎病毒，并有助于降低肝硬化和肝细胞癌的风险，对市场成长产生积极影响。除此之外，不断增加的研发（R＆D）活动、医疗保健行业的显着增长以及政府促进公共卫生的各种倡议的实施正在为市场创造积极的前景。

本报告回答的关键问题

  • 2023年全球肝病治疗市场规模有多大？
  • 2024-2032年全球肝病治疗市场的预期成长率是多少？
  • 推动全球肝病治疗市场的关键因素是什么？
  • COVID-19 对全球肝病治疗市场有何影响？
  • 根据治疗类型，全球肝病治疗市场的细分如何？
  • 根据疾病类型，全球肝病治疗市场的细分如何？
  • 基于最终用户的全球肝病治疗市场的细分情况如何？
  • 全球肝病治疗市场的重点区域有哪些？
  • 全球肝病治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肝病治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 抗病毒药物
    • 市场走向
    • 市场预测
  • 免疫抑制剂
    • 市场走向
    • 市场预测
  • 疫苗
    • 市场走向
    • 市场预测
  • 免疫球蛋白
    • 市场走向
    • 市场预测
  • 皮质类固醇
    • 市场走向
    • 市场预测
  • 标靶治疗
    • 市场走向
    • 市场预测
  • 化疗
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依疾病类型

  • 肝炎
    • 市场走向
    • 市场预测
  • 自体免疫疾病
    • 市场走向
    • 市场预测
  • 非酒精性脂肪肝（NAFLD）
    • 市场走向
    • 市场预测
  • 癌症
    • 市场走向
    • 市场预测
  • 遗传性疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 门诊手术中心
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
Product Code: SR112024A5023

The global liver disease treatment market size reached US$ 23.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:

The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, disease type and end user.

Breakup by Treatment Type:

Antiviral Drugs

Immunosuppressants

Vaccines

Immunoglobulins

Corticosteroids

Targeted Therapy

Chemotherapy

Breakup by Disease Type:

Hepatitis

Autoimmune Diseases

Non-alcoholic Fatty Liver Disease (NAFLD)

Cancer

Genetic Disorders

Others

Breakup by End User:

Hospitals

Ambulatory Surgical Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global liver disease treatment market in 2023?
  • 2. What is the expected growth rate of the global liver disease treatment market during 2024-2032?
  • 3. What are the key factors driving the global liver disease treatment market?
  • 4. What has been the impact of COVID-19 on the global liver disease treatment market?
  • 5. What is the breakup of the global liver disease treatment market based on the treatment type?
  • 6. What is the breakup of the global liver disease treatment market based on the disease type?
  • 7. What is the breakup of the global liver disease treatment market based on the end user?
  • 8. What are the key regions in the global liver disease treatment market?
  • 9. Who are the key players/companies in the global liver disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Antiviral Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunoglobulins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Corticosteroids
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Targeted Therapy
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Chemotherapy
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Hepatitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Genetic Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Astellas Pharma Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Emergent BioSolutions Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Gilead Sciences Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 GlaxoSmithKline plc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novartis AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sanofi S.A.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
    • 14.3.14 Takeda Pharmaceutical Company Limited
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio
      • 14.3.14.3 Financials
      • 14.3.14.4 SWOT Analysis
    • 14.3.15 Viatris Inc.
      • 14.3.15.1 Company Overview
      • 14.3.15.2 Product Portfolio
      • 14.3.15.3 Financials

List of Figures

  • Figure 1: Global: Liver Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Liver Disease Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Liver Disease Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Liver Disease Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 5: Global: Liver Disease Treatment Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Liver Disease Treatment Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Liver Disease Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Liver Disease Treatment (Antiviral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Liver Disease Treatment (Antiviral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Liver Disease Treatment (Immunosuppressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Liver Disease Treatment (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Liver Disease Treatment (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Liver Disease Treatment (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Liver Disease Treatment (Immunoglobulins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Liver Disease Treatment (Immunoglobulins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Liver Disease Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Liver Disease Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Liver Disease Treatment (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Liver Disease Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Liver Disease Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Liver Disease Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Liver Disease Treatment (Hepatitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Liver Disease Treatment (Hepatitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Liver Disease Treatment (Autoimmune Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Liver Disease Treatment (Autoimmune Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Liver Disease Treatment (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Liver Disease Treatment (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Liver Disease Treatment (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Liver Disease Treatment (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Liver Disease Treatment (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Liver Disease Treatment (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Liver Disease Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Liver Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Liver Disease Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Liver Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Liver Disease Treatment Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Liver Disease Treatment Industry: SWOT Analysis
  • Figure 90: Global: Liver Disease Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Liver Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liver Disease Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Liver Disease Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Liver Disease Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Liver Disease Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Liver Disease Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Liver Disease Treatment Market: Competitive Structure
  • Table 7: Global: Liver Disease Treatment Market: Key Players